Transmissible Spongiform Encephalopathies: Decontamination of Agent and FDA-Regulated Products Food and Drug Administration Transmissible Spongiform Encephalopathies.

Slides:



Advertisements
Similar presentations
Prions (CJD) and Processing of Reusable Medical Products
Advertisements

Validating Sterilization of Medical Devices
Copyright © 2006 Thomson Delmar Learning. ALL RIGHTS RESERVED. 1 PowerPoint ® Presentation for Introduction to Dental Assisting Module: Disease Prevention.
HAND HYGIENE PRESENTER: CATHERINE W NGUGI 1. Objectives n Identify the single most effective way to reduce the spread of hospital associated infections.
Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.
OSHAs blood borne pathogens standard A written exposure control plan designed to eliminate or minimize worker exposure Compliance with universal precautions.
Sterilization and disinfection. Sterilization can be define as the process by which all forms of microbial life including bacterial spores & vegetative.
CDRH - CBER TSE INSTRUMENT DECONTAMINATION PROJECT Stanley Brown, Katharine Merritt, Terry Woods, Scott McNamee and Deanna Busick CDRH/ OST / DMMS & DLS.
Essential Steps to Safe, Clean Care Essential Steps AIM: Designed as a framework to support local organisations providing and commissioning health and.
TSE: Instrument Management in Surgery and Dentistry Current CDC Recommendations Lynne Sehulster, PhD, M(ASCP) Division of Healthcare Quality Promotion.
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 6 Infection Control: Clinical Procedures.
3.03 Understand support services
Clean? Disinfect? Sterilize? What does it all mean??
Infection Control AHS II Unit F. Standard Precautions Sometimes called “Universal” precautions Sometimes called “Universal” precautions Used to break.
Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.
WY MSHA State Grant Program BLOOD BORNE PATHOGENS AND UNIVERSAL PRECAUTIONS TRAINING.
Prevention of HIV in Health Care Facilities Dr KANUPRIYA CHATURVEDI.
Antoinette Barton-Gooden Patient and Health Care worker Safety.
STERLIZATION AND CROSS INFECTION CONTROL IN THE DENTAL PRACTICE:
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
Introduction To the pr EN ISO Project norm
P1 1 Biosafety: Practical Considerations (Use As Reference For Practical)
Prions: Proteins Gone Bad
Decontamination of Surfaces Contaminated with Prions Dr. Gerald McDonnell.
October 31, 2005HHS/FDA/CDRH1. October 31, 2005HHS/FDA/CDRH2 Scientific Issues in Evaluating Products Intended to Decontaminate Surgical instruments Exposed.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
 Radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. They may be given to the patient in several different.
WHY ARE WE HERE? OSHA BB Pathogen standard The more you know, the better you will perform in real situations!
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Risk-Based Sourcing for Bovine Materials in FDA-regulated Medical Products: Introduction and General Considerations FDA TSE Advisory Committee Meeting.
Sterilization of Medical Devices: Bodhisatwa Das.
TSEAC Meeting July 18, 2003 Topic 4 Ruth Solomon, M.D. DHT/OCTGT Methods to decontaminate facilities and equipment used in recovery and processing of HCT/Ps.
TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
STERLIZATION AND CROSS INFECTION CONTROL IN THE DENTAL PRACTICE: part 2 BY. DR HINA ADNAN DNT 362.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Visible Light Disinfection System Rutala, Gergen, Kanamori, Sickbert-Bennett, Weber Uses blue-violet range of visible light in nm region through.
Environmental Cleaning Tool Kit
Transmissible Spongiform Encephalopathies: Two Models for Evaluating Effects of Cleaning and Decontamination Measures on Residual Agent Infectivity Food.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Infection Control And Sterilization In Dentistry
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Infection Control and Medical Asepsis
David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.
Course Code: NUR 240 Lecture ( 3). 1.The Risk of Infection is always Present in every Hospital. 2.Identify frequency of nosocomial infection.
ASEPTIC TECHNIQUE IN HEALTHCARE. MICROBIAL GROWTH FOLLOWING FACTORS INFLUENCE MICROBIAL GROWTH: TEMPERATURE PH, OR THE VALUES USED IN CHEMISTRY TO EXPRESS.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
Proteolytic Inactivation of prions; a biological solution to TSE decontamination. Dickinson J*, Murdoch H*, Sutton JM*, Crabb, W. D.#, Bott, R#, Penet,
Handling and Disposal of Infectious Wastes
APIC Greater NY Chapter 13 Journal Club Session January 20, 2016 by Yuri Castillo RN BSN CIC Infection Prevention and Control Department /
Housekeeping.
GlovesGloves. ObjectivesObjectives KEY CONCEPTS you will learn: When gloves should be worn Which type of glove to use Glove requirements for clinical.
VARIANT CREUTZFELDT-JACOB DISEASE (vCJD) AND GASTROINTESTINAL ENDOSCOPY.
3.03 Understand support services PP2
3.03 Understand support services
19 April 2017 Kyle Willey, CIC.
Hand Hygiene. HLTIN301A Comply with infection control policies and procedures in health work.
3.03 Understand support services
3.03 Understand support services
INFECTION CONTROL.
FDA TSE Advisory Committee Meeting
Sterilization September 2018.
3.03 Understand support services PP2
3.03 Understand support services
Infection Control and Dental Care
3.03 Understand support services
3.03 Understand support services
Presentation transcript:

Transmissible Spongiform Encephalopathies: Decontamination of Agent and FDA-Regulated Products Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee 17 July 2003 Holiday Inn Bethesda, Maryland David M. Asher, MD Laboratory of Bacterial, Parasitic and Unconventional Agents Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research and Review Center for Biologics Evaluation and Research United States Food and Drug Administration address:

FDA, TSEs and Decontamination Mission: Protection from contaminated products Inactivation of TSE agents is context-dependent:  Scrapie agent in aqueous suspension is substantially if not always completely inactivated by moist heat.  Scrapie agent is not completely inactivated after drying. TSE agents are substantially inactivated in solutions of NaOH, NaOCl, [other chemicals]. WHO consultants recommended decontamination in “healthcare environments” using combined NaOH or NaOCl and moist heat. Other authorities doubt need for NaOH, NaOCl. Situations requiring TSEAC advice (CDRH, CBER, [CDER]: Instruments, surfaces) Situations for which TSEAC advice is not solicited (FDA: Food, feeds [Other: USDA, EPA])

Six Cases of CJD Plausibly Attributable to Contaminated Neurosurgical Instruments Report No of Cases (months post exposure) Cleaning Procedures Terminal Sterilization Nevin & al. (Brain 1960;83:519) [69yom,68yom,47yof] Probable source case of 1, 2 from Will & Matthews. J Neurol Neurosurg Psych 1982:45:235 2 or 3 (15 *,17 *,17 ? ) [*Source case identified later.] ? Routine surgical ? Dry heat Bernoulli & al. (Lancet 1977;i:478) [23yof,17yom] 2 (16,20) Source case confirmed. Benzene, ethanol Formaldehyde vapor Foncin & al. (Revue Neurologique 1980;136:280) [48yom] 1 (28) Source case confirmed. ? Routine surgical Dry heat (Poupinel oven)

Variable Effects of Heat on TSE Infectivity: Examples (Taylor DM. Vet J 2000;159:10-17) Strains of TSE agent differ in thermal stability:  301V BSE > 22A Scr > 263K Scr > ME7 Scr Dry heat: some strains survived 200 o C x 1 h Autoclaving reduces infectivity titer markedly, sometimes to limit of detection but not always.  Gravity displacement: Some infectivity survived at 132 o C x 1 h  Vacuum:  Unmacerated tissue lost all detectable infectivity after 134 o C- 138 o C x 18 min  Macerated tissue contained residual infectivity after 134 o C-138 o C x 1 h Conclusion: In “worst-case” scenarios, autoclaving has not been validated to decontaminate all TSE agents completely.

Four Factors to Consider in Assessing Whether a Contaminating Instrument Might Transmit CJD: Example of Uncertainties Infectivity of CJD patient tissue touching instrument  UK estimate for brain:  10 7 human ID50/g  USA estimate for brain: 10 5 human ID50/g Reduction in infectivity remaining on instrument by decontamination (cleaning, chemical, heat, &c)  UK estimate for cleaning: 10 2 to 10 3  USA estimate for cleaning: 10 4  UK & USA estimates for disinfection+ sterilization: >10 3  Tissues of subsequent patient exposed to instrument  Susceptibility of exposed patient _____________________________________________________________ UK: CJD Incidents Panel. Consultation Paper 2001 USA: Rutala WA, Weber DJ. Clin Infec Dis 2001;32:

Infectivity of Neural Tissues from 300 Humans with TSEs (Brown P et al. Ann Neurol 1994;35: )

Estimated Amounts of Infectivity in Tissues of Persons Dying with TSEs (Brown P et al. Ann Neurol 1994;35: ) Human TSE brains usually contained  10,000 primate intracerebral lethal doses per gram of tissue (“pooled” data LD50 per gm) positive brains tested in dilutions > 1 % (sCJD 21, kuru 3, GSS 2, fCJD 1) - 73 % (19/26) of brains were positive at 1:10, % (6/15) were positive at 1:1,000, % (1/8) were positive at 1:100,000,000 - None of 6 was positive at 1:1,000,000,000 Primate brains contained 10 5 to 10 7 LD50/gm Other human tissues ?  1000 LD50/gm

Infectivity of Materials from Humans with TSEs: Uncertainties of Negative Transmission Attempts (Brown P et al. Ann Neurol 1994;35: ) Small sample sizes were studied.  Small numbers of specimens  Small volumes of tissues and fluids Species barriers reduce sensitivity of infectivity assays.  (Incubation periods in primates drop on first primate-to-primate serial passage, then remain stable on subsequent passages. That suggests the presence of some species barriers between non-human primates and humans.) Limits of detection in primates for infectivity present in human materials are unknown. There may be variation in distribution of infectivity in tissues of humans with TSEs. - Clinical illness - Asymptomatic incubation periods (not amenable to study)

Advice Offered in UK and USA Concerning Surgical Instruments Exposed to CJD Agent l UK: “While the risk of transmitting CJD through invasive medical procedures is uncertain, precautionary action should be taken … withdrawing all those that might be implicated as soon as possible. … In general, instruments that have undergone ten or fewer decontamination cycles since being used on the index patient with CJD should be incinerated.” l USA: “… [Cleanable critical or semicritical] devices [in contact with high-risk tissues of CJD patient] … (e.g., surgical instruments) can be cleaned and then sterilized by autoclaving either at 134 o C for  18 min in a prevacuum sterilizer or at 121 o C-132 o C for 1 h in a gravity displacement sterilizer.” _____________________________________________________________________ UK: CJD Incidents Panel. Consultation Paper 2001 USA: Rutala WA, Weber DJ. Clin Infec Dis 2001;32:

WHO General Considerations for Effective TSE Agent Decontamination in Healthcare Settings (WHO: Decontamination is “context-dependent” and may not be completely effective under all circumstances. Cleaning facilitates decontamination by reducing infectivity and “organic load.” Use the best “validated” methods available. Use “orthogonal” strategy––two different methods––whenever possible.

WHO-Recommended Procedures for Handling of TSE- agent-contaminated Surgical Instruments: WHO Caveats (WHO/CDS/CSR/APH/2000.3) Single-use instruments are strongly recommended. For maximum safety, destroy re-usable instruments. Quarantine instruments potentially exposed to TSE agents until Dx of TSE is ruled out. “In some healthcare situations [when instruments cannot be discarded] … less effective methods may be preferred.”

WHO-Recommended Procedures for Handling of TSE-agent-contaminated Surgical Instruments: WHO Caveats (WHO/CDS/CSR/APH/2000.3) “Policy makers are encouraged to adopt the highest decontamination methods feasible until studies are published which clarify the risk of re-using contaminated instruments.” Recommended alternative decontamination methods are listed “in order of decreasing effectiveness.”

WHO-Recommended Procedures for Handling of TSE-agent- contaminated Heat-Resistant Surgical Instruments (WHO/CDS/CSR/APH/2000.3) Incineration: “Preferred method for all instruments exposed to high infectivity tissues.”  ___________________________________________________________________________________________________________________________________________________ Other methods “ in order of more to less effectiveness”:  NaOH 1N+gravity-displacement (GD) autoclave 121 o C x 30’; clean; rinse; routine sterilization 2. NaOH or NaOCl ppm x 60’ ; transfer to H 2 0; GD autoclave 121 o C x 60’; clean &c 3. NaOH or NaOCl x 60’ rm temp; rinse; GD autoclave 121 o C or porous-load (PL) autoclave 134 o C x 60’; clean &c 4. NaOH, boil x 10’ atm; clean &c 5. NaOCl (preferred) or NaOH (alternative) rm temp temp x 60’; clean &c

WHO-Recommended Procedures for Handling of TSE-agent-contaminated Heat-Resistant Surgical Instruments CONTINUED (WHO/CDS/CSR/APH/2000.3) Other methods “ in order of more to less effectiveness” (continued): 6. Autoclave at 134 o C for 18 minutes. * ________________________________________________ * “In [worst-case] scenarios (brain tissue bake- dried on to surfaces) infectivity will be largely but not completely removed.”

WHO-Recommended Decontamination Regimens for Surfaces & Heat-Sensitive Instruments (modified from WHO/CDS/CSR/APH/2000.3) Flood with NaOH 2N or NaOCl ( ppm available Cl) and let stand x 60’.  Mop and rinse with water.  Dispose of absorbents and fluids as contaminated waste. Alternative (not fully satisfactory)  If surfaces cannot tolerate exposure to NaOH or NaOCl, then clean thoroughly and decontaminate with a partially effective method. (Then consider the surfaces to be potentially contaminated.)

Four Situations Requiring Decisions Regarding TSE Agent Decontamination TSE confirmed or suspected TSE not suspected High-risk tissue ??? Lower-risk tissue ???

TSE Agent Decontamination: TSEAC Program July 2003 General principles of cleaning and decontamination for TSE agents (R. Rohwer) Review of effective decontamination and WHO advice (D. Taylor) Experience with hospital decontamination in UK and USA (P. Edwards*, W. Rutala) Incineration (E. Rau) Decontamination models (S. Brown, D. Asher, C. Weissmann, C. Kempf)  * in absentia, presentation by P. Piccardo, CBER

TSE Agent Decontamination: TSEAC Issues 18 July 2003 CDRH: Reprocessing of medical devices (L. Gill, M. O’Lone, C. Durfor) CBER: Decontamination of facilities and equipment used to process human-tissue-derived and plasma products (R. Solomon, E. Heck, D. Scott, C. Kempf, A. Bailey) [CDER: Aware of relevance to FDA-regulated drugs made with human-derived or animal-derived materials]  CFSAN, CVM: Production processes for food and feeds differ markedly from CDRH/ CBER/ CDER products.  USDA, EPA: Share some common issues with FDA but have different advisory committees.